Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 12/20 | 0.61 |
| ▸ | MTTP | P55157 | 10/20 | 0.61 |
| ▸ | APOB | P04114 | 7/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492503 | 0.89 | SMO (0.51) | SMOMTTPAPOB | |
| SCHEMBL6491901 | 0.88 | MTTP (0.64) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL6793327 | 0.86 | SMO (0.59) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL6490003 | 0.85 | MTTP (0.65) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL7985005 | 0.84 | SMO (0.55) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL6492134 | 0.84 | MTTP (0.50) | SMOMTTPAPOB | |
| SCHEMBL6490835 | 0.83 | SMO (0.50) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL6499684 | 0.82 | SMO (0.50) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL6906387 | 0.80 | SMO (0.50) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL7080705 | 0.79 | SMO (0.49) | SMOMTTPAPOBTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMO 2580/4885MTTP 677/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.